10-K: MoonLake Immunotherapeutics Advances SLK Pipeline

MoonLake Immunotherapeutics' 2025 annual report details significant clinical progress for Sonelokimab across multiple inflammatory diseases, despite increased net losses.

Summary

• MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing Sonelokimab (SLK), a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, for inflammatory skin and joint diseases.
• The MIRA trial (Phase 2b HS) met its primary endpoint, with 43% of patients treated with SLK 120mg achieving HiSCR75 at week 12, and 24-week data showed further improvements (57% HiSCR75).
• The combined Phase 3 VELA program for HS demonstrated clinically meaningful and statistically significant improvement across all primary and key secondary endpoints (p<0.001).
• VELA-1 (Phase 3 HS) achieved statistical significance for all primary and key secondary endpoints (HiSCR75, delta to placebo of 17%, p<0.001), with 34% of patients achieving HiSCR75 at week 16.
• VELA-2 (Phase 3 HS) showed similar SLK response rates (34% HiSCR75), but a higher-than-expected placebo arm (24.9%) led to the study not achieving statistical significance for the week 16 primary endpoint using the composite strategy (p=0.053).
• Interim long-term data from VELA trials (February 2026) indicated monthly maintenance treatment with SLK led to further improvements, with 69% HiSCR75 in VELA-1 and 67% in VELA-2 after 52 weeks.
• The VELA-TEEN trial (Phase 3 adolescent HS), initiated in January 2025, showed 67% HiSCR75 response at week 16 in an interim analysis (n=21).
• The FDA confirmed that MoonLake may establish substantial evidence of effectiveness for SLK in HS without additional clinical trials, advising inclusion of MIRA and VELA data for the Biologics License Application (BLA).
• BLA submission for SLK in adult and adolescent HS is expected in the second half of 2026, with a potential U.S. commercial launch in the second half of 2027.
• The ARGO trial (Phase 2b PsA) met its primary endpoint (ACR50) with 46% of patients on 60mg SLK achieving response at week 12, and 24-week data showed continued significant improvements.
• Phase 3 IZAR-1 and IZAR-2 trials for PsA were initiated in November 2024, with IZAR-1 enrollment completed in February 2026. Readouts are expected in mid-2026 and second half of 2026, respectively.
• The LEDA trial (Phase 2 PPP) demonstrated clinically meaningful and statistically significant benefit, with 64% mean PPPASI change and 39% PPPASI75 at week 16.
• SLK received Fast Track designation from the FDA for moderate-to-severe PPP in February 2026, and a Phase 3 trial is expected to commence in Q3 2026.
• The S-OLARIS trial (Phase 2 axSpA) showed clinically meaningful and statistically significant benefit, with 81% ASAS40 response at week 12, and imaging data confirmed significant inflammation reduction.
• The safety profile of SLK was consistent across all reported studies with no new safety signals observed.
• Net loss for the year ended December 31, 2025, was $230.3 million, a 90.0% increase from $121.2 million in 2024.
• Research and development expenses increased by 79.9% to $202.9 million in 2025, primarily due to clinical trials and pre-launch inventory production.
• General and administrative expenses increased by 38.4% to $42.0 million in 2025, supporting organizational growth.
• As of December 31, 2025, cash, cash equivalents, and short-term marketable securities totaled $394.0 million, expected to fund operations into the second half of 2027.
• A $500.0 million Loan and Security Agreement was entered into in March 2025, with an initial $75.0 million tranche funded. $175.0 million of committed capital was reduced due to missed VELA-2 milestones.
• An amendment to the Loan and Security Agreement in February 2026 resulted in a $25.0 million second tranche draw, with up to $400.0 million remaining available.
• A public offering in November 2025 raised net proceeds of $72.4 million from the sale of 7,142,857 Class A Ordinary Shares.
• An ongoing securities class action lawsuit (Peters v. MoonLake Immunotherapeutics) alleges false or misleading statements related to SLK clinical benefits; the company denies allegations and intends to vigorously defend.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as largely positive due to strong clinical data across multiple indications for SLK, particularly the FDA's confirmation of sufficient evidence for BLA submission in HS and Fast Track designation for PPP. However, the missed primary endpoint in VELA-2 and increased net losses temper the overall sentiment.

Positives

• SLK's MIRA trial (Phase 2b HS) met its primary endpoint (HiSCR75) with 43% of patients on 120mg achieving response at week 12, with further improvements to 57% at 24 weeks.
• The combined Phase 3 VELA program for HS demonstrated clinically meaningful and statistically significant improvement across all primary and key secondary endpoints (p<0.001).
• VELA-1 (Phase 3 HS) achieved statistical significance for all primary and key secondary endpoints (HiSCR75, delta to placebo of 17%, p<0.001).
• Interim long-term VELA data (52 weeks) showed continued improvements in HiSCR75 response rates (69% in VELA-1, 67% in VELA-2).
• Interim VELA-TEEN (adolescent HS) data showed a strong 67% HiSCR75 response at week 16.
• The FDA confirmed that substantial evidence of effectiveness (SEE) for SLK in HS can be established without additional clinical trials, supporting the planned BLA submission.
• The ARGO trial (Phase 2b PsA) met its primary endpoint (ACR50) with 46% response at week 12, and 24-week data showed continued significant improvements, numerically outperforming adalimumab.
• FDA and EMA supported the proposed Phase 3 programs for SLK in both HS and PsA.
• IZAR-1 (Phase 3 PsA) enrollment has been completed.
• The LEDA trial (Phase 2 PPP) demonstrated clinically meaningful and statistically significant benefit, with 64% mean PPPASI change and 39% PPPASI75 at week 16.
• SLK received Fast Track designation from the FDA for moderate-to-severe PPP, potentially accelerating its development pathway.
• The S-OLARIS trial (Phase 2 axSpA) demonstrated clinically meaningful and statistically significant benefit, with 81% ASAS40 response at week 12, supported by objective imaging and biomarker data.
• The safety profile of SLK was consistent across all reported trials with no new safety signals observed, including absence of signals in key events of interest with IL-17A and F therapies.
• Successful manufacturing of Process Performance Qualification batches and initiation of pre-launch inventory stockpiling for SLK.
• Strong cash, cash equivalents, and short-term marketable securities position of $394.0 million as of December 31, 2025, providing funding into the second half of 2027.
• Successful public offering in November 2025 raised $72.4 million in net proceeds.

Negatives

• VELA-2 (Phase 3 HS) failed to achieve statistical significance in the week 16 primary endpoint using the composite strategy (p=0.053) due to a higher-than-expected placebo arm (24.9% vs historical 13-18%).
• The company incurred a significant net loss of $230.3 million for the year ended December 31, 2025, a 90.0% increase from the $121.2 million loss in 2024.
• Operating losses are expected to continue for the foreseeable future, at least for the next two years.
• Failure to achieve Tranche 2 and Tranche 4 milestones under the Loan and Security Agreement resulted in a reduction of committed capital by $175.0 million.
• The company is substantially dependent on the success of SLK, its single asset, which carries inherent development risks.
• An ongoing securities class action lawsuit (Peters v. MoonLake Immunotherapeutics) alleges false or misleading statements related to SLK clinical benefits.
• As a holding company, MoonLake depends on distributions from its subsidiary MoonLake AG, which are subject to a 35% Swiss federal dividend withholding tax with no current relief.

Risks

• Substantial dependence on the success of SLK; ongoing and anticipated clinical trials of SLK may not be successful.
• Reliance on certain licensing rights from MHKDG and RCT that can be terminated if agreements are breached or diligence obligations are not met.
• Incurred significant losses since inception and expects to incur significant losses for the foreseeable future; may not achieve or sustain profitability.
• Limited operating history and no products approved for commercial sale.
• Never successfully completed the regulatory approval process for any product candidates.
• Results of preclinical testing and early clinical trials may not be predictive of later clinical trials; clinical trial results may not satisfy regulatory requirements.
• Preliminary, interim data from clinical trials may change as more patient data become available and are subject to audit and verification.
• Difficulty enrolling patients in clinical trials could delay or prevent successful completion or marketing approvals.
• Substantial competition from major pharmaceutical and biotechnology companies, including other IL-17A and IL-17F inhibitors.
• SLK may have a safety profile that could prevent regulatory approval, marketing acceptance, or limit commercial potential.
• Inability to raise additional capital when needed or on acceptable terms could force delays, reductions, or elimination of development programs or commercialization efforts.
• Reliance on third parties (CMOs) to produce and process SLK; failure by these third parties could adversely affect the business.
• Uncertainty in protecting patents and other proprietary rights, leading to possible loss of competitive advantage.
• Geopolitical events and global economic conditions (e.g., public health crises, conflicts, tariffs, inflation, interest rates) could adversely affect preclinical studies, clinical trials, business, and financial condition.
• Regulatory approval processes are complex, time-consuming, and unpredictable; delays or failure to obtain approvals would materially impair revenue generation.
• Extensive ongoing regulatory obligations and review post-approval, potentially leading to significant additional expense or penalties for non-compliance.
• Disruptions at regulatory agencies (FDA, SEC) due to funding shortages or global health concerns could hinder timely review and approval.
• Unfavorable pricing regulations and/or third-party coverage and reimbursement policies could prevent competitive pricing.
• Employees, contractors, and collaborators may engage in misconduct or improper activities, including noncompliance with regulatory standards.
• Exposure to broadly applicable fraud and abuse and other healthcare laws and regulations.
• Healthcare system under significant financial pressure to reduce costs, potentially impacting drug payment and reimbursement rates.
• Pharmaceutical and biological product marketing subject to substantial regulation; failure to comply could result in penalties.
• Failure to comply with environmental, health, and safety laws could result in fines or penalties.
• Subject to laws and regulations related to privacy, data protection, information security, and consumer protection; non-compliance could harm the business.
• Subject to U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws.
• The Cayman Islands Economic Substance Act may affect operations and require additional resources for compliance.
• Current and future legislation (e.g., IRA) may increase difficulty and cost to obtain marketing approval and commercialize drugs, affecting prices.
• Adverse legislative or regulatory tax changes could negatively impact financial condition (e.g., R&D expenditure amortization).
• Dependence on key personnel; difficulty attracting and retaining qualified personnel could hinder business strategy.
• Difficulties in managing anticipated growth in organization size and scope.
• Cybersecurity incidents or failures in IT systems could disrupt operations and impact financial condition.
• Patent terms may be inadequate to protect competitive position.
• Issued patents could be found invalid or unenforceable.
• Failure to identify relevant third-party patents or incorrect interpretation of their scope could adversely affect ability to develop and market SLK.
• Claims challenging inventorship of patents and other intellectual property.
• Patent infringement claims or need to file claims to protect IP could result in substantial costs and liability.
• License from MHKDG may be subject to retained rights.
• Difficulty securing first-tier technologies against competitors.
• Product candidates regulated as biologics may face competition from biosimilars.
• Price volatility of Class A Ordinary Shares; risk of securities litigation.
• Sales of Class A Ordinary Shares by principal shareholders/management could cause price decline.
• Principal shareholders and management own significant percentage of stock, exerting influence.
• Anti-takeover provisions in organizational documents could delay or prevent change of control.
• Indemnification obligations to officers and directors may result in significant cost.
• No anticipated cash dividends; capital appreciation is sole source of gain.
• Future issuances of debt/equity may adversely affect company and dilute shareholders.
• May become a foreign private issuer, exempt from certain U.S. domestic public company provisions, potentially affording less shareholder protection.

Future Outlook

MoonLake Immunotherapeutics expects to complete one-year VELA-1 and VELA-2 trials in Q2 2026 and the VELA-TEEN trial in mid-2026, with a BLA submission for SLK in adult and adolescent HS anticipated in H2 2026 and a potential U.S. commercial launch in H2 2027. For PsA, primary endpoint readouts for IZAR-1, IZAR-2, and P-OLARIS trials are expected between mid-2026 and end of 2026, followed by a supplemental BLA submission. A Phase 3 trial for PPP is expected to commence in Q3 2026. The company plans to invest further in commercial capabilities, establish a U.S. presence in 2026, and continue building manufacturing capabilities and intellectual property. While existing capital is projected to fund operations into H2 2027, significant operating losses are expected to continue for at least the next two years, necessitating future financing through equity, debt, or collaborations.

Management Comments

• "We envision SLK as a key therapeutic alternative in our initial target indications and potentially in multiple other IL-17 driven inflammatory conditions."
• "Our vision is to elevate treatment goals for inflammatory skin and joint diseases."
• "Our strategy is centered on developing SLK as, to our knowledge, the first ever Nanobody in clinical development for our selected indications."
• "We believe that our management team is well-positioned to identify assets that have attractive risk/reward profiles and that can be rapidly advanced to market approval, supplemented by our expertise and capabilities."
• "We believe that our facilities are sufficient to meet our current needs. We also believe we will be able to obtain additional space, as needed, on commercially reasonable terms."
• "We believe that the success of our human capital management investments is evidenced by our low employee turnover, a metric which is regularly reviewed by our board of directors as part of its oversight of our human capital strategy."
• "We pride ourselves on having a strong, inclusive and positive culture based on our shared mission and values."
• "The defendants deny the allegations of wrongdoing in the Class Actions and intend to vigorously defend against the claims."

Industry Context

StockSavvy.ai notes that MoonLake Immunotherapeutics is positioning SLK as a differentiated therapeutic alternative in a competitive landscape for inflammatory skin and joint diseases. The focus on IL-17A and IL-17F inhibition, particularly with a Nanobody platform, aims to address unmet needs where existing treatments may fall short. The rapid progression of multiple indications (HS, PsA, PPP, axSpA) through clinical trials, coupled with positive Phase 2 and Phase 3 data, suggests a strong development pipeline. The receipt of Fast Track designation for PPP underscores regulatory recognition of SLK's potential in areas with limited approved therapies. However, the industry faces increasing pressure on drug pricing and reimbursement, as highlighted by the Inflation Reduction Act of 2022, which could impact future commercialization efforts.

Comparison to Industry Standards

• In PsA, SLK 60mg and 120mg (with induction) numerically outperformed adalimumab, an active reference arm, on the primary endpoint (ACR50) and all key secondary endpoints.
• SLK's PsA responses surpassed those for adalimumab and were higher when indirectly compared to competitors using the same active reference arm as a standard.
• SLK showed 16-29 percentage-point differences to the reference adalimumab arm in composite scores (e.g., ACR50+PASI90, ACR50+PASI100, ACR70+PASI100, MDA), comparatively higher than competitors using the same reference arm.
• The placebo response rate in VELA-1 (HS) of 17.5% at week 16 was within the historical Phase 3 range of 13% to 18%.
• The placebo response rate in VELA-2 (HS) of 24.9% at week 16 was higher than expected, impacting statistical significance.
• UCB's bimekizumab is mentioned as the only other IL-17A and IL-17F inhibitor beyond SLK that has received approval or is in late-stage clinical development, indicating a limited direct competitor set for this specific mechanism.
• Competitors mentioned include companies developing and/or marketing IL-17A inhibitors (Novartis AG, Eli Lilly and Co, Zura Bio Ltd, LEO Pharma), IL-23 inhibitors (AbbVie, Janssen, Sun Pharmaceutical, Almirall), IL-12/23 inhibitors (Janssen), TNF alpha inhibitors (AbbVie, Pfizer, Janssen, UCB), TYK2 inhibitors (Bristol Myers Squibb), JAK inhibitors (AbbVie, Incyte, Pfizer), IL1a/IL1b inhibitors (Abbvie, Avalo Therapeutics), OX40L inhibitors (Sanofi), and IRAK4 degraders (Kymera Therapeutics Inc).

Corporate Governance

Legal Proceedings

• On October 15, 2025, a class action lawsuit, Bridgewood v. MoonLake Immunotherapeutics, et al., was filed in the U.S. District Court for the Southern District of New York, alleging claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 based on allegedly false or misleading statements related to SLK clinical benefits and prospects. This action was voluntarily dismissed without prejudice on October 22, 2025.
• On October 17, 2025, a second putative class action, Peters v. MoonLake Immunotherapeutics, et al., was filed in the U.S. District Court for the Southern District of New York, naming the same defendants and containing identical allegations. Lead plaintiff and lead counsel were appointed on January 6, 2026. The company denies the allegations and intends to vigorously defend against the claims, but cannot estimate the reasonably possible loss or range of loss.

Related Party Transactions

• The company entered into a License Agreement with Merck Healthcare KGaA (MHKDG), an affiliate of Merck KGaA, Darmstadt, Germany, which involved an upfront cash payment and an issuance of equity representing a 9.9% ownership stake in MoonLake Immunotherapeutics AG to MHKDG.
• The company also entered into an agreement with Research Cooperation Technologies, Inc. (RCT) and MHKDG for a royalty-bearing, nonexclusive, sublicensable right and license related to a manufacturing process.

Stakeholder Impact

• Shareholders: Potential for increased value from successful clinical trials and commercialization, but also risk of dilution from future capital raises, stock price volatility, and impact from ongoing litigation. Anti-takeover provisions may limit ability to obtain a premium for shares.
• Patients: Potential for improved treatment options for moderate-to-severe HS, PsA, PPP, and axSpA with SLK, especially given positive clinical trial results and Fast Track designation for PPP.
• Employees: Continued growth in employee numbers, competitive compensation, and focus on inclusion and safety. Risk of impact from financial performance or strategic shifts.
• Creditors: Secured Loan and Security Agreement with Hercules Capital, Inc., pledging substantially all assets. Covenants limit operational flexibility.
• Regulatory Authorities: Ongoing interactions with FDA and EMA for clinical trial approvals, BLA submissions, and post-marketing surveillance.
• Third-party Manufacturers/CROs: Continued reliance on these partners for drug substance, drug product, and clinical trial execution.

Next Steps

• Complete one-year VELA-1 and VELA-2 trials in Q2 2026.
• Complete six-month VELA-TEEN clinical trial in mid-2026.
• Submit a Biologics License Application (BLA) for SLK in adult and adolescent HS in H2 2026.
• Expect a first commercial launch in the United States for HS in H2 2027, subject to FDA approval.
• Readout of primary and key secondary endpoints of IZAR-1 clinical trial in mid-2026.
• Readout of primary and key secondary endpoints of IZAR-2 clinical trial in H2 2026.
• Expect results of the P-OLARIS trial at the end of 2026.
• Seek regulatory approval for PsA after completion of studies through submission of a supplemental BLA.
• Commence a Phase 3 clinical trial in PPP in Q3 2026.
• Evaluate next steps to complete clinical development of SLK in axSpA.
• Continue non-clinical research to refine understanding of SLK/Nanobody biology and potential impact.
• Prepare for commercialization of SLK, including building marketing, access, and pricing functions.
• Establish a presence in the United States in 2026 to build sales, marketing, and distribution infrastructure.
• Continue investing in manufacturing capabilities, including additional technology transfers and process improvements.
• Continue stock-piling drug substance as pre-launch inventory in 2026.
• Continue extending global intellectual property portfolio.
• May initiate clinical trials of SLK in other indications.
• May supplement current strategy with in-licensing or acquisition of additional product candidates.
• End-of-Phase 2 meeting with the FDA planned for PPP in H1 2026.

Key Dates

Recommendation

MoonLake Immunotherapeutics presents a mixed but generally promising picture. The strong positive clinical data for SLK across multiple indications (HS, PsA, PPP, axSpA) and the FDA's confirmation for BLA submission in HS are significant catalysts for future growth and potential commercialization. The Fast Track designation for PPP further de-risks that program. However, the failure of VELA-2 to meet its primary endpoint due to a high placebo response, coupled with a substantial increase in net losses and the ongoing securities litigation, introduces notable uncertainties. While the company has a solid cash runway into H2 2027, future capital raises will be necessary for full commercialization. The stock is likely to experience volatility as these various factors play out. A 'Hold' recommendation reflects the balance between the strong clinical progress and the financial and operational risks.

Keywords

MoonLake Immunotherapeutics, Sonelokimab, SLK, Nanobody, IL-17A, IL-17F, Hidradenitis Suppurativa, HS, Psoriatic Arthritis, PsA, Axial Spondyloarthritis, axSpA, Palmoplantar Pustulosis, PPP, Biotechnology, Clinical Trials, Phase 3, Phase 2, FDA, EMA, Regulatory Approval, BLA, Commercialization, Financial Results, 10-K, Biopharmaceutical, Dermatology, Rheumatology, Orphan Drug, Fast Track, Intellectual Property, Capital Raise